NAYA Biosciences (NAYA) 10-K 29 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 16, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	INVO Bioscience, Inc.,
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		143,784,700
Entity Public Float			$ 24,477,000
Amendment Flag	false
Entity Central Index Key	1,417,926
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash	$ 25,759	$ 152,404
Accounts receivable, net	86,697	2,794
Inventory	58,879	85,210
Prepaid expense	63,050	10,980
Total current assets	234,385	251,388
Property and equipment, net	15,700	15,700
Other Assets:
Capitalized patents, net	16,328	19,138
Total other assets	16,328	19,138
Total assets	266,413	286,226
Current liabilities
Accounts payable and accrued liabilities, including related parties	960,725	974,872
Accrued compensation	3,955,190	3,576,390
Note payable - related party	210,888	210,888
Convertible notes	0	10,000
Total current liabilities	5,126,803	4,772,150
Notes payable, long-term	131,722	131,722
Total liabilities	5,258,525	4,903,872
Commitments and contingencies (Note 11)
Stockholder’s deficiency
Preferred Stock, $.0001 par value; 100,000,000 shares authorized; No shares issued and outstanding as of December 31, 2017 and 2016	0	0
Common Stock, $.0001 par value; 200,000,000 shares authorized; 142,132,374 and 140,596,646 issued and outstanding as of December 31, 2017 and December 31, 2016, respectively.	14,213	14,059
Additional paid-in capital	13,638,806	13,311,263
Accumulated deficit	(18,645,131)	(17,942,968)
Total stockholder’s deficiency	(4,992,112)	(4,617,646)
Total liabilities and stockholders’ deficiency	$ 266,413	$ 286,226

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	100,000,000	100,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	142,132,374	140,596,646
Common Stock, shares outstanding	142,132,374	140,596,646

CONSOLIDATED STATEMENTS OF LOSS

CONSOLIDATED STATEMENTS OF LOSSES - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 282,145	$ 50,901
Cost of goods sold	51,954	15,094
Gross margin	230,191	35,807
Selling, general and administrative expenses	870,612	2,146,221
Total operating expenses	870,612	2,146,221
Loss from operations	(640,421)	(2,110,414)
Other (Income) Expenses:
Loss on settlement of debt	40,869
Interest expense	20,873	13,838
Total other expenses	61,742	13,838
Loss before income taxes	(702,163)	(2,124,252)
Provisions for income taxes	0	0
Net loss	$ (702,163)	$ (2,124,252)
Basic net loss per weighted average shares of common stock (in Dollars per share)	$ 0	$ (0.02)
Diluted net loss per weighted average shares of common stock (in Dollars per share)	$ 0	$ (0.02)
Basic weighted average number of shares of common stock (in Shares)	141,305,050	139,186,557
Diluted weighted average number of shares of common stock (in Shares)	141,305,050	139,186,557

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIENCY) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2015	$ 13,708	$ 12,048,006	$ (15,818,716)	$ (3,757,002)
Balance, shares (in Shares) at Dec. 31, 2015	137,085,646
Common stock issued for services	$ 351	1,263,257	0	1,263,608
Common stock issued for services (in Shares)	3,511,000
Net loss for the twelve months			(2,124,252)	(2,124,252)
Balance at Dec. 31, 2016	$ 14,059	13,311,263	(17,942,968)	$ (4,617,646)
Balance, shares (in Shares) at Dec. 31, 2016	140,596,646			140,596,646
Common stock issued for services	$ 88	215,044	0	$ 215,132
Common stock issued for services (in Shares)	876,672
Common stock issued for cash	$ 32	54,593	0	54,625
Common stock issued for cash, shares (in Shares)	318,056
Common stock issued for convertible notes & interest	$ 34	57,906	0	57,940
Common stock issued for convertible notes & interest (in Shares)	341,000
Net loss for the twelve months			(702,163)	(702,163)
Balance at Dec. 31, 2017	$ 14,213	$ 13,638,806	$ (18,645,131)	$ (4,992,112)
Balance, shares (in Shares) at Dec. 31, 2017	142,132,374			142,132,374

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (702,163)	$ (2,124,252)
Adjustments to reconcile net loss to net cash used in operating activities:
Excess value of warrant liability	40,869	0
Accretion of convertible debt discount	215,132	1,263,608
Depreciation and amortization	2,810	1,878
Changes in assets and liabilities:
Accounts receivable	(83,903)	(1,448)
Inventory	26,331	(19,790)
Prepaid expenses and other current assets	(52,070)	(10,980)
Accounts payable and accrued expenses	(5,346)	82,814
Accrued interest - related party	(1,730)	(1,730)
Accrued compensation	378,800	486,000
Net cash provided by operating activities	(181,270)	(323,900)
Cash flows from investing activities:
Payments for property and equipment	0	(15,700)
Net cash used in investing activities	0	(15,700)
Cash flows from financing activities:
Proceeds from the sale of common stock	54,625	0
Net cash (used in) provided by financing activities	54,625	0
Increase in cash and cash equivalents	(126,645)	(339,600)
Cash and cash equivalents at beginning of period	152,404	492,004
Cash and cash equivalents at end of period	25,759	152,404
Cash paid during the period for:
Interest	0	0
Taxes	0	0
Common stock issued upon conversion of debt	$ 57,940	0
Note payable issued for accounts payable		$ 131,722

NOTE 1 - SUMMARY OF SIGNIFICANT

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) General INVO Bioscience, Inc. (“the Company”) offers novel solutions in assisted reproductive technologies while expanding geographic and affordable access to the global reproductive health care community. Our primary focus is the manufacture and sale of the INVOcell device and the INVO technology to assist infertile couples in having a baby. We designed our INVOcell device and our INVO procedure to provide an alternative infertility treatment for the patient and the clinician. The INVO procedure is less expensive and simpler to perform than most comparable infertility treatments currently. The simplicity of the INVO procedure relates to the ability to potentially perform the INVO procedure in a physician’s practice rather than in a specialized facility at a much lower cost overall than current infertility treatments. We believe that the INVO procedure will make infertility treatment more readily available throughout the world. The INVO procedure is significantly less costly than conventional IVF. The INVOcell device and INVO procedure facilitates conception and embryo development inside the woman’s body, rather than in a dish in a laboratory, which is an attractive feature for most couples. Through December 31, 2017, we have generated minimal revenues, have incurred significant expenses and have sustained losses. Consequently, our operations are subject to all the risks inherent in the establishment of a new business enterprise. In May 2008, the Company received notice that the INVOcell product meets all of the essential requirements of the relevant European Directive(s), and received CE marking. The CE marking (also known as CE mark) is a mandatory conformity mark on many products placed on the single market in the European Economic Area (EEA). The CE marking (an acrony m for the French “Conformitй Europйenne”) certifies that a product has met EU health, safety and environmental requirements, which ensure consumer safety. On November 3, 2015, the Company issued a press release reporting the U.S. Food and Drug Administration (“FDA”) has granted the Company’s de novo request for the INVOcell to allow the marketing, sale and use in the United States. With CE Marking, the Company possess the necessary regulatory authority to distribute its product in the European Economic Area (Includes: The European Union, Canada, Australia, and New Zealand); we can also distribute in India, Africa and most parts of South America and the Middle East. (B) Basis of Presentation On December 5, 2008, the Company completed a share exchange with Emy’s Salsa Aji Distribution Company, Inc. (“Emy’s”), a publicly registered shell corporation with no significant assets or operations. Emy’s was incorporated on July 11, 2005, under the laws of the State of Nevada under the name Certiorari Corp. In connection with the share exchange, INVO Bioscience became Emy’s wholly-owned subsidiary and the INVO Bioscience shareholders acquired control of Emy’s. The Company accounted for the transaction as a recapitalization and the Company is the surviving entity. In connection with the share exchange, Emy’s shareholders retained 14,937,500 shares. Effective with the Agreement, all previously outstanding shares of Common Stock owned by the Company’s shareholders were exchanged for an aggregate of 38,307,500 shares of Emy’s common stock. Effective with the Agreement, Emy’s changed its name to INVO Bioscience, Inc. All references to “Common Stock,” “share” and “per share” amounts have been retroactively restated to reflect the exchange ratio of 357.0197 shares of INVO Bioscience Common Stock for one share of Emy’s common stock outstanding immediately prior to the merger as if the exchange had taken place as of the beginning of the earliest period presented. The accompanying consolidated financial statements present the historical financial condition, results of operations and cash flows of the Company prior to the merger with Emys. The accompanying consolidated financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. (C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. (D) Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had the following amounts of cash and cash equivalents on its balance sheets as of December 31, 2017 and 2016 of $25,759 and $152,404, respectively. (E) Inventory Inventories consist of work in process (WIP) and finished products and are stated at the lower of cost or market; using the first-in, first-out (FIFO) method as a cost flow convention. (F) Property and Equipment The Company records property and equipment at cost. Depreciation and amortization are provided using the straight-line method over the estimated economic lives of the assets, which are from 3 to 7 years. The Company capitalizes the expenditures for major renewals and improvements that extend the useful lives of property and equipment. Expenditures for maintenance and repairs are charged to expense as incurred. The Company reviews the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by a comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value. (G) Stock Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”). This statement requires the Company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period in which the employee is required to provide service in exchange for the award, which is usually the vesting period. ( H) Loss Per Share Basic loss per share calculations are computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include securities or other contracts to issue common stock that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2017 and 2016, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Twelve Months Ended December 31, 2017 2016 Loss to common shareholders (Numerator) $ (702,163 ) $ (2,124,252 ) Basic and diluted weighted-average number of common shares outstanding (Denominator) 141,305,050 139,186,557 The Company has excluded the following dilutive securities from the calculation of fully-diluted shares outstanding because the result would have been anti-dilutive: Twelve Months Ended December 31, 2017 2016 Effect of dilutive common stock equivalents: Warrants - - Convertible notes and interest 3,391,300 3,430,547 Total 3,391,300 3,430,547 ( I) Fair Value of Financial Instruments ASC 825-10-50, “Disclosures about Fair Value of Financial Instruments,” (formerly SFAS No. 107) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. Effective January 1, 2008, the Company adopted ASC 820-10, “Fair Value Measurements” (SFAS 157), which provides a framework for measuring fair value under GAAP. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs. (J) Income Taxes The Company accounts for income taxes under the ASC 740-10-05, “Accounting for Income Taxes” (SFAS 109). Under ASC 740-10, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. On December 22, 2017, the Tax Cuts (TCJA) was signed into law by the President of the United States. TCJA is a tax reform act that among other things, reduced corporate tax rates to 21 percent effective January 1, 2018. FASB ASC 740, Income Taxes , requires deferred tax assets and liabilities to be adjusted for the effect of a change in tax laws or rates in the year of enactment, which is the year in which the change was signed into law. Accordingly, the Company adjusted its deferred tax assets and liabilities at December 31, 2017, using the new corporate tax rate of 21 percent. See Note 10. (K) Business Segments The Company operates in one segment and therefore segment information is not presented. (L) Concentration of Credit Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (FDIC) limits. As of December 31, 2017, the Company had no cash balances in excess of FDIC limits. (M) Revenue Recognition The Company will recognize revenue on arrangements in accordance with ASC 605-10 formerly Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” and No. 104, “Revenue Recognition.” In all cases, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured. (N) Long- Lived Assets Long-lived assets and certain identifiable assets related to those assets are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. If the non-discounted future cash flows of the enterprise are less than their carrying amount, their carrying amounts are reduced to the fair value and an impairment loss recognized. There was no impairment recorded from January 5, 2007 (inception) to December 31, 2017. (O) Reclassifications Certain reclassifications have been made in prior year’s financial statements to conform to classifications used in the current year. (P) Recent Accounting Pronouncements In May 2017, the FASB issued ASU No. 2017-09, Stock Compensation - Scope of Modification Accounting, which provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The ASU requires that an entity should account for the effects of a modification unless the fair value (or calculated value or intrinsic value, if used), vesting conditions and classification (as equity or liability) of the modified award are all the same as for the original award immediately before the modification. The ASU becomes effective for the Company on January 1, 2018, and should be applied prospectively to an award modified on or after the adoption date. Early adoption is permitted, including adoption in any interim period. The Company will apply this standard for any awards that are modified after January 1, 2018. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment, which simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, current U.S. GAAP requires the performance of procedures to determine the fair value at the impairment testing date of assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, the amendments under this ASU require the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The ASU becomes effective for the Company on January 1, 2020. The amendments in this ASU should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In August 2016, the FASB issued ASU No. 2016-15 which amends ASC Topic 230, “Classification of Certain Cash Receipts and Cash Payments.” The amendments in this update address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The update outlines the classification of specific transactions as either cash inflows or outflows from financing activities, operating activities, investing activities or non-cash activities. This guidance is effective for interim and annual reporting periods beginning after December 15, 2017. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), to increase transparency and comparability among organizations by recognizing a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either operating or financing, with such classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, and early adoption is permitted. We are currently evaluating the impact ASU 2016-02 will have on our consolidated financial statements and associated disclosures. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), to clarify the principles of recognizing revenue and create common revenue recognition guidance between U.S. GAAP and International Financial Reporting Standards. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized at an amount that reflects the consideration expected to be received in exchange for such goods or services. In addition, ASU 2014-09 requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The ASU is effective for fiscal years beginning after December 15, 2017. The new revenue standard is principle based and interpretation of those principles may vary from company to company based on their unique circumstances. It is possible that interpretation, industry practice, and guidance may evolve as companies and the accounting profession work to implement this new standard. The Company is still in the process of evaluating the effect of the new standard on the Company’s historical financial statements and disclosures. While the Company has not completed its evaluation, the Company currently believes that the impact to revenue and expense recognized will not be material to any of the years presented. Management does not believe that any other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying condensed consolidated financial statements.

NOTE 2 GOING CONCERN

NOTE 2 GOING CONCERN	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 GOING CONCERN The Company commenced operations in December 2008. During the year ended December 31, 2017, the Company had a net loss of $702,163 and cash used in operations $181,270. At December 31, 2017, the Company had a working capital deficiency of $4,892,418 and a stockholder deficiency of $4,992,112. This raises substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan.

NOTE 3 INVENTORY

NOTE 3 INVENTORY	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 3 INVENTORY The Company had inventory in the following amounts: December 31, 2017 December 31, 2016 Work in Process $ 24,357 $ 27,986 Finished Goods 34,522 57,224 Total Inventory $ 58,879 $ 85,210

NOTE 4 PROPERTY AND EQUIPMENT

NOTE 4 PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 PROPERTY AND EQUIPMENT The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows: Estimated Useful Life Molds 3 to 7 years December 31, 2017 December 31, 2016 Manufacturing Equipment- Molds $ 50,963 $ 50,963 Accumulated Depreciation (35,263 ) (35,263 ) $ 15,700 $ 15,700 The Company recorded $0 and $0 depreciation expense in 2017 and 2016 as its earlier equipment was fully depreciated. The 2016 asset addition has not been put into production as of December 31, 2017.

NOTE 5 PATENTS

NOTE 5 PATENTS	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	NOTE 5 PATENTS The Company capitalizes the initial expense related to establishing the patent by country and then amortizes the expense over the life of the patent, typically 20 years. It then expenses annual filing fees to maintain the patents. The Company regularly reviews the value of the patent in the market place in proportion to the expense it must spend to maintain the patent. The Company has recorded the following patent costs: December 31, 2017 December 31, 2016 Total Patents $ 77,743 $ 77,743 Accumulated Amortization (61,415 ) (58,605 ) Patent costs, net $ 16,328 $ 19,138 The Company recorded amortization expense as follows: Twelve Months Ended December 31, 2017 2016 $ 2,810 $ 1,878 In 2011, the decision was made to not to pay the renewal fees and expedite the amortization of the original patent which expired in 2012. It was also decided to not spend its limited funds in defending the INVO Block patent as it only has value to the Company. The Company continues to pay the annual renewal fees on its active patents. Estimated amortization expense as of December 31, 2017 is as follows: Years ended December 31, 2018 $ 4,536 2019 4,536 2020 1,809 2021 1,809 2022 and thereafter 3,638 Total $ 16,328

NOTE 6 CONVERTIBLE NOTES AND NO

NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Long-term Debt [Text Block]	NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE Convertible Notes - Bridge Notes During 2009, the Company issued senior secured convertible notes (“Bridge Notes”) payable to investors in the aggregate amount of $545,000. The Bridge Notes carry interest rates ranging between 10-12% and were due in full one year from the date of issuance and are past due. Both the Bridge Notes and the accrued interest thereon are convertible into Restricted Common Stock of the Company at a conversion price of $0.10 per share (the “Original Conversion Price”). If the Company were to issue any new shares of common stock within 24 months of the date of the Bridge Notes at a price below the Original Conversion Price, then the conversion price of the Bridge Notes would be adjusted to reflect the new lower price. In addition to the Bridge Notes, the Company issued warrants to purchase 5,750,000 shares of the Company’s Common Stock at a price of $0.20 per share as of the date of this filing. All the warrants have expired. The Company valued the conversion feature of the Bridge Notes and the warrants issued via the Black-Scholes valuation method. The total fair value calculated for the conversion feature was $1,473,710; $151,826 was allocated to discount on the Bridge Notes, and $1,341,884 was charged to operations. The total fair value calculated for the warrants was $1,719,666; $393,174 was allocated to discount on the Bridge Notes, and $1,326,492 was charged to operations. The aggregate discount on the Bridge Notes for the conversion feature and the warrants was $545,000, and the aggregate amount charged to operations was $2,668,371 which was recorded as a derivative liability on the Company’s consolidated balance sheet. From November 2009 through May 2015 $535,000 of the principal of the Bridge Notes were converted into shares of Restricted Common Stock. In March 2017, the Company converted the last Bridge Note in the amount of $10,000 and accrued interest into shares of common stock. The Company negotiated this conversion at a price lower than the conversion price stated in the original Bridge Note documents because the Bridge Note was past due. This conversion was treated as a restructure of debt on the Company’s financial statements for the six months ended June 30, 2017. $10,000 of the Bridge Notes and accrued interest were converted into 341,000 shares of restricted common stock resulting in a loss on debt settlement in the amount of $40,869. The principal balances of the Convertible Notes was $0 and $10,000 for 2017 and 2016, respectively. This last note was converted in Q1 2017. The related interest for the twelve months ended December 31, 2017 and 2016 was $0 and $750, respectively. Notes Payable In August 2016, INVO Bioscience converted a long time vendor’s outstanding accounts payable balance of $131,722 into a three (3) year 5% notes payable. The note provides for interest only payments on the first and second anniversaries of the note. The note is payable in full along with any outstanding accrued interest on the third anniversary. The Company has the right to prepay the note at any time without a premium or penalty. The interest on this note for the years ended December 31, 2017 and 2016 was $9,330 and $2,760 respectively.

NOTE 7 NOTE PAYABLE AND OTHER R

NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS On September 18, 2008, the Company entered into a related party transaction with Dr. Claude Ranoux. Dr. Ranoux was then the President, Director and Chief Scientific Officer of the Company; as of the date of this filing he is a Director. Dr. Ranoux had loaned funds to the Company to sustain its operations since January 5, 2007 (inception). Dr. Ranoux’s total original cumulative investment as of December 31, 2008 was $96,462, as of December 31, 2017 and 2016 it is $21,888 (“the Principal Amount”) in INVO Bioscience. On March 26, 2009, the Company and Dr. Ranoux agreed to re-write the agreement to a non-convertible note payable bearing interest at 5% per annum, the term of the note had been extended, and has been extended a couple of additional times, the current repayment date is October 31, 2018. The Company and Dr. Ranoux can jointly decide to repay the loan earlier without prepayment penalties. During the twelve months ended December 31, 2017 and 2016, $0 were repaid on the principal of the loan. On March 5, 2009, the Company entered into a related party transaction with Kathleen Karloff, the Chief Executive Officer and a Director of the Company. Ms. Karloff provided a short-term loan in the amount of $75,000 bearing interest at 5% per annum to the Company to fund operations. In May 2009, Ms. Karloff loaned to the Company an additional $13,000, making her total cumulative loan $88,000 as of December 31, 2011. This note was due on September 15, 2009, which has since been extended a few times to its current date of October 31, 2018. During the twelve months ended December 31, 2014, Ms. Karloff loaned the Company an additional $66,000 at an interest rate of 0% by entering into a note payable agreement in satisfaction of expenses incurred by her for amounts previously advanced to the Company. This note currently has the same expiration date as the others which is October 31, 2018. On December 28, 2009 James Bowdring, the brother of Director Robert Bowdring invested $100,000 acquiring 666,667 shares of restricted common stock. In April 2011, the Company issued a new short term convertible note (“Q211 Note”) payable to James Bowdring in the amount of $50,000. The Q211 Note carries a 10% interest rate and was due in full, two months from the date of issuance. The note was past due and is partially still open, as of this date the balance is $25,000. The Q211 Note is convertible into Common Stock of the Company at a conversion price of $0.03 per share, subject to adjustments. In addition to the Q211 Note, the Company issued warrants to purchase 1,666,667 shares of the Company’s Common Stock at a price of $0.03 per share, as of this date the warrants have expired. The Company valued the Q211 Note’s warrants issued as consideration for the notes payable via the Black-Scholes valuation method. The total fair value calculated for the conversion was approximately $39,500, and for the warrants was approximately $45,500 both of which were recorded as a derivative liability on the Company’s balance sheet. In September 2011, the Company made a principal payment on the Q211 Note in the amount of $25,000. In November 2011, the Company issued a new convertible note (“Q411 Note”) payable to James Bowdring in the amount of $10,000. The Q411 Note carries a 10% interest rate and is due in full, two months from the date of issuance. The Q411 Note is convertible into Common Stock of the Company at a conversion price of $0.01 per share, subject to adjustments. In addition to the Q411 Note, the Company issued warrants to purchase 500,000 shares of the Company’s Common Stock at a price of $0.02 per share, as of this date the warrants have expired. The Company valued the Bridge Note’s warrants issued as consideration for the notes payable via the Black-Scholes valuation method. The total fair value calculated for the conversion option was $2,345, and for the warrants was $4,076 both of which were recorded as a derivative liability on the Company’s balance sheet. In Other Related Party Transactions, we have been renting our corporate office from Forty Four Realty Trust which is owned by James Bowdring, the brother of Director, Robert Bowdring since November 2012. It is a month to month rental arrangement for less than the going fair market real estate rental rate. We have been paying $4,800 annually since 2012. In addition the Company purchases stationary supplies and marketing items at discounted rates from Superior Printing & Promotions which is also owned by James Bowdring and is in the same building as our corporate office. INVO Bioscience spent $1,700 and $4,100 with Superior during 2017 and 2016, respectively. Principal balances of the Related Party loans were as follows: December 31, 2017 December 31, 2016 Claude Ranoux Note $ 21,888 $ 21,888 James Bowdring – Q211 Note 25,000 25,000 James Bowdring- Q411 Note 10,000 10,000 Kathleen Karloff Note 154,000 154,000 Total $ 210,888 $ 210,888 Interest expense on the Related Party loans was $11,543 and $13,088 for the years ended December 31, 2017 and 2016, respectively. Accounts payable and accrued liabilities balances include expenses reports for Ms. Karloff, Dr. Ranoux and Mr. Bowdring for expenses they paid for personally related to travel or normal business expenses and are represented in the following table: December 31, 2017 2016 Accounts payable and accrued liabilities $ 38,000 $ 39,000

NOTE 8 STOCKHOLDERS' EQUITY

NOTE 8 STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 STOCKHOLDERS’ EQUITY Twelve Months Ended December 31, 2017 In March 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 196,000 shares of restricted common stock with a fair value of $59,242 to service providers. In March 2017, pursuant to Section 4(2) of the Securities Act, the Company negotiated the conversion of $10,000 of past due Bridge Notes and accrued interest into 341,000 shares of restricted common stock resulting in a loss on debt settlement in the amount of $40,869. In April 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 51,750 shares of restricted common stock with a fair value of $17,201 to service providers. In June 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 99,412 shares of restricted common stock with a fair value of $30,898 to service providers. In September 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 133,960 shares of restricted common stock with a fair value of $28,576 to service providers. In September 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 262,500 shares of restricted common stock for cash proceeds of $44,625. In November 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 395,550 shares of restricted common stock with a fair value of $79,215 to service providers. In November 2017, pursuant to Section 4(2) of the Securities Act, the Company issued 55,556 shares of restricted common stock for cash proceeds of $10,000. Twelve Months Ended December 31, 2016 In May 2016, , the Company issued 3,000,000 shares of common stock with a fair value of $1,080,000 to officers for compensation. In May 2016, the Company issued 511,000 shares of common stock with a fair value of $183,608 to service providers for services performed.

NOTE 9 STOCK OPTIONS AND WARRAN

NOTE 9 STOCK OPTIONS AND WARRANTS	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 STOCK OPTIONS AND WARRANTS Stock Options As of December 31, 2017 and 2016, the Company does not have any outstanding or committed and unissued stock options. Warrants As of December 31, 2017 and 2016, the Company does not have any outstanding or committed and unissued warrants.

NOTE 10 INCOME TAXES

NOTE 10 INCOME TAXES	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 10 INCOME TAXES The Company has adopted ASC 740-10, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company’s total deferred tax liabilities, deferred tax assets, and deferred tax asset valuation allowances are as of December 31 are as follows: December 31, 2017 December 31, 2016 Total deferred tax assets $ 3,730,000 $ 5,235,000 Less valuation allowance (3,730,000 ) (5,235,000 ) Total deferred tax liabilities - - Net deferred tax asset (liability) $ - $ - Those amounts have been presented in the company’s financial statements as of December 31, as follows: December 31, 2017 2016 Deferred tax asset $ - $ - Deferred tax liability - - Net deferred tax asset (liability) $ - $ - The company has a loss carry forward of $9.1 million that may be offset against future taxable income. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cut and Jobs Act (the “Tax Act”). The Tax Act establishes new tax laws that affects 2018 and future years, including a reduction in the U.S. federal corporate income tax rate to 21%, effective January 1, 2018 . For certain deferred tax assets and deferred tax liabilities, we have recorded a provisional decrease of $1,680,000 , with a corresponding net adjustment to valuation allowance of $1,680,000 as of December 31, 2017. Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which is uncertain. Those amounts are therefore presented on the Company’s balance sheets as a non-current asset. Utilization of the net operating loss carry forwards may be subject to substantial annual limitations, which may result in the expiration of net operating loss carry forwards before utilization.

NOTE 11 COMMITMENTS AND CONTING

NOTE 11 COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 COMMITMENTS AND CONTINGENCIES A) Operating Leases In November 2012, INVO Bioscience entered into a below market, month to month rental agreement with Forty Four Realty Trust with for the space it requires. Forty Four Realty Trust is owned by investor James Bowdring, the brother of Director Robert Bowdring. B) Litigation INVO Bioscience, Inc., and two of its directors have been, since 2010, defending litigation brought by investors in an alleged predecessor of INVO Bioscience. On March 24, 2010, INVO Bioscience, Inc. and its corporate affiliate, Bio X Cell, Inc., Claude Ranoux, and Kathleen Karloff were served an Amended Complaint, the original of which was filed on December 31, 2009 at the Suffolk Superior Court Business Litigation Session by two terminated employees of Medelle Corporation (also named as a co-defendant but no longer active), who are also attorneys, and a former investor in and creditor of Medelle. These plaintiffs allege various claims of wrongdoing relating to the sale of assets of Medelle to Dr. Ranoux. Plaintiffs claim that Dr. Ranoux, Ms. Karloff, and Medelle (and therefore INVO Bioscience as an alleged successor corporation) violated alleged duties owed to plaintiffs in connection with the sale. Separate claims were also alleged against INVO Bioscience. Dr. Ranoux, Ms. Karloff, and INVO Bioscience have challenged these allegations, which they believe are baseless. The transfer of the assets of Medelle was professionally handled by an independent third party, after approval by the Medelle Board of Directors, representing a majority of its shareholders. Medelle’s Board voted to proceed with an assignment for the benefit of creditors (AFBC) and gave complete authority to the President & CEO at that time (neither Dr. Ranoux nor Ms. Karloff) to work with the third-party assignee and to get the best possible price for those assets. The third party was responsible for notifying all the appropriate parties and for filing notices in various professional publications and newspapers of Medelle’s intention to sell its assets. The third party also contacted numerous large medical device and bio-pharma companies to learn if they would be interested in acquiring the assets. After a private sale was deemed unlikely, the assignee of the assets elected to proceed with a sealed-bid auction of the assets. On the day of the auction, Dr. Ranoux submitted the only bid and was awarded the assets, upon full payment. During 2010, Dr. Ranoux, Ms. Karloff, and INVO Bioscience filed Motions to Dismiss as to all claims, pursuant to M.R.Civ. P. 12(b)(6). In a written Decision rendered on November 12, 2010, the judge dismissed all claims against INVO, Bio X Cell, and Ms. Karloff, and also dismissed the claims against Dr. Ranoux alleging civil conspiracy and breach of M.G.L. c. 93A. The judge denied Dr. Ranoux’s motion to dismiss the remaining breach of fiduciary duty and fraud claims. The plaintiffs allege in their Amended Complaint that Dr. Ranoux committed fraud by failing to inform them of the details of the Medelle auction. The claims against Dr. Ranoux that survived the November 2010 dismissal order were submitted to binding arbitration. On February 15, 2013, the mutually-agreed arbitrator ruled in favor of Dr. Ranoux. The award held that Dr. Ranoux did not withhold information about the auction of Medelle’s assets and expressed doubt that the plaintiffs would have invested the resources necessary to make a beneficial use of the assets. The arbitrator’s award then was confirmed by the Superior Court on August 21, 2013. The Superior Court’s confirmation of the award was affirmed on appeal on October 20, 2013 by the Massachusetts Appeals Court. The Massachusetts Supreme Judicial Court then denied further appellate review. On October 18, 2016, following motions and argument, the Superior Court issued a memorandum of decision and order denying plaintiffs’ motion for entry of default judgment and assessment of damages against Medelle and allowed the motion of INVO Bioscience, Bio X Cell, and Ms. Karloff for entry of final judgment of dismissal. The foregoing order was converted to a final judgment dismissing all claims against all defendants and entered on the docket on October 27, 2016. On November 28, 2016, plaintiffs filed an amended notice of appeal from the Superior Court’s decision of October 17, 2016 and the subsequent judgment entered on October 27, 2016. The appeal further challenges the order of dismissal from November, 2010. Plaintiffs did not appeal from the dismissal of the claims against Ms. Karloff, so the judgment in her favor is now final, leaving claims against INVO Bioscience, Bio X Cell, Medelle, and Dr. Ranoux. INVO Bioscience and Bio X Cell intend a vigorous opposition to the current appeal, consistent with their previous positions that no breach of duty occurred in the sale of Medelle’s assets. It is assumed that Dr. Ranoux will oppose the appeal as well. Outside of the above-mentioned litigation, neither INVO Bioscience nor Bio X Cell, our wholly-owned subsidiary, either directly or indirectly, are involved in any lawsuit outside the ordinary course of business, the disposition of which would have a material effect upon either our results of operation, financial position, or cash flows. C) Employee Agreements The Company had employment agreements for officers, executives and employees of the Company in place. The agreements have since expired and have not been renewed as the Company has not had the proper funds to meet its commitment but has continued to accrue amounts annually for the work that has been performed. The employees and directors are continuing to work based on good faith and belief in the Company and the INVOcell product. D) Consulting Agreements The Company has a verbal agreement beginning in March, 2013 with its former CFO, Robert Bowdring, who is currently a Director, to assist where necessary in the financial and administrative areas of the Company for compensation to be equivalent to the others working in the organization. The Company had an agreement which began in August, 2011 with an Advisory Board Member who assisted the Company in its sales and marketing areas for stock compensation. This member’s agreement was not renewed in September 2016 when it expired.

NOTE 12 SUBSEQUENT EVENTS

NOTE 12 SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 12 SUBSEQUENT EVENTS In January 2018, the Company issued 1,000,000 shares of common stock with a fair value of $115,000 to officers & directors for compensation. In January 2018, the Company issued 100,000 shares of common stock for cash proceeds of $15,000. In January 2018, the Company issued 441,426 shares of common stock with a fair value of $52,864 to service providers for services performed. In February 2018, the Company issued 90,900 shares of common stock with a fair value of $10,000 to service providers for services performed. In March 2018, the Company issued 20,000 shares of common stock with a fair value of $3,800 to service providers for services performed.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation On December 5, 2008, the Company completed a share exchange with Emy’s Salsa Aji Distribution Company, Inc. (“Emy’s”), a publicly registered shell corporation with no significant assets or operations. Emy’s was incorporated on July 11, 2005, under the laws of the State of Nevada under the name Certiorari Corp. In connection with the share exchange, INVO Bioscience became Emy’s wholly-owned subsidiary and the INVO Bioscience shareholders acquired control of Emy’s. The Company accounted for the transaction as a recapitalization and the Company is the surviving entity. In connection with the share exchange, Emy’s shareholders retained 14,937,500 shares. Effective with the Agreement, all previously outstanding shares of Common Stock owned by the Company’s shareholders were exchanged for an aggregate of 38,307,500 shares of Emy’s common stock. Effective with the Agreement, Emy’s changed its name to INVO Bioscience, Inc. All references to “Common Stock,” “share” and “per share” amounts have been retroactively restated to reflect the exchange ratio of 357.0197 shares of INVO Bioscience Common Stock for one share of Emy’s common stock outstanding immediately prior to the merger as if the exchange had taken place as of the beginning of the earliest period presented. The accompanying consolidated financial statements present the historical financial condition, results of operations and cash flows of the Company prior to the merger with Emys. The accompanying consolidated financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had the following amounts of cash and cash equivalents on its balance sheets as of December 31, 2017 and 2016 of $25,759 and $152,404, respectively.
Inventory, Policy [Policy Text Block]	Inventory Inventories consist of work in process (WIP) and finished products and are stated at the lower of cost or market; using the first-in, first-out (FIFO) method as a cost flow convention.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment The Company records property and equipment at cost. Depreciation and amortization are provided using the straight-line method over the estimated economic lives of the assets, which are from 3 to 7 years. The Company capitalizes the expenditures for major renewals and improvements that extend the useful lives of property and equipment. Expenditures for maintenance and repairs are charged to expense as incurred. The Company reviews the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by a comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Codification subtopic 718-10, Compensation (“ASC 718-10”). This statement requires the Company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period in which the employee is required to provide service in exchange for the award, which is usually the vesting period.
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share Basic loss per share calculations are computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include securities or other contracts to issue common stock that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2017 and 2016, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Twelve Months Ended December 31, 2017 2016 Loss to common shareholders (Numerator) $ (702,163 ) $ (2,124,252 ) Basic and diluted weighted-average number of common shares outstanding (Denominator) 141,305,050 139,186,557 The Company has excluded the following dilutive securities from the calculation of fully-diluted shares outstanding because the result would have been anti-dilutive: Twelve Months Ended December 31, 2017 2016 Effect of dilutive common stock equivalents: Warrants - - Convertible notes and interest 3,391,300 3,430,547 Total 3,391,300 3,430,547
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC 825-10-50, “Disclosures about Fair Value of Financial Instruments,” (formerly SFAS No. 107) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. Effective January 1, 2008, the Company adopted ASC 820-10, “Fair Value Measurements” (SFAS 157), which provides a framework for measuring fair value under GAAP. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the ASC 740-10-05, “Accounting for Income Taxes” (SFAS 109). Under ASC 740-10, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. On December 22, 2017, the Tax Cuts (TCJA) was signed into law by the President of the United States. TCJA is a tax reform act that among other things, reduced corporate tax rates to 21 percent effective January 1, 2018. FASB ASC 740, Income Taxes , requires deferred tax assets and liabilities to be adjusted for the effect of a change in tax laws or rates in the year of enactment, which is the year in which the change was signed into law. Accordingly, the Company adjusted its deferred tax assets and liabilities at December 31, 2017, using the new corporate tax rate of 21 percent. See Note 10.
Segment Reporting, Policy [Policy Text Block]	Business Segments The Company operates in one segment and therefore segment information is not presented.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (FDIC) limits. As of December 31, 2017, the Company had no cash balances in excess of FDIC limits.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company will recognize revenue on arrangements in accordance with ASC 605-10 formerly Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” and No. 104, “Revenue Recognition.” In all cases, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Long- Lived Assets Long-lived assets and certain identifiable assets related to those assets are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. If the non-discounted future cash flows of the enterprise are less than their carrying amount, their carrying amounts are reduced to the fair value and an impairment loss recognized. There was no impairment recorded from January 5, 2007 (inception) to December 31, 2017.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain reclassifications have been made in prior year’s financial statements to conform to classifications used in the current year.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2017, the FASB issued ASU No. 2017-09, Stock Compensation - Scope of Modification Accounting, which provides guidance on which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The ASU requires that an entity should account for the effects of a modification unless the fair value (or calculated value or intrinsic value, if used), vesting conditions and classification (as equity or liability) of the modified award are all the same as for the original award immediately before the modification. The ASU becomes effective for the Company on January 1, 2018, and should be applied prospectively to an award modified on or after the adoption date. Early adoption is permitted, including adoption in any interim period. The Company will apply this standard for any awards that are modified after January 1, 2018. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment, which simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, current U.S. GAAP requires the performance of procedures to determine the fair value at the impairment testing date of assets and liabilities (including unrecognized assets and liabilities) following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, the amendments under this ASU require the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The ASU becomes effective for the Company on January 1, 2020. The amendments in this ASU should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In August 2016, the FASB issued ASU No. 2016-15 which amends ASC Topic 230, “Classification of Certain Cash Receipts and Cash Payments.” The amendments in this update address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The update outlines the classification of specific transactions as either cash inflows or outflows from financing activities, operating activities, investing activities or non-cash activities. This guidance is effective for interim and annual reporting periods beginning after December 15, 2017. We are evaluating what impact, if any, the adoption of this guidance will have on our financial condition, results of operations, cash flows or financial disclosures. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), to increase transparency and comparability among organizations by recognizing a right-of-use asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either operating or financing, with such classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, and early adoption is permitted. We are currently evaluating the impact ASU 2016-02 will have on our consolidated financial statements and associated disclosures. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), to clarify the principles of recognizing revenue and create common revenue recognition guidance between U.S. GAAP and International Financial Reporting Standards. Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized at an amount that reflects the consideration expected to be received in exchange for such goods or services. In addition, ASU 2014-09 requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The ASU is effective for fiscal years beginning after December 15, 2017. The new revenue standard is principle based and interpretation of those principles may vary from company to company based on their unique circumstances. It is possible that interpretation, industry practice, and guidance may evolve as companies and the accounting profession work to implement this new standard. The Company is still in the process of evaluating the effect of the new standard on the Company’s historical financial statements and disclosures. While the Company has not completed its evaluation, the Company currently believes that the impact to revenue and expense recognized will not be material to any of the years presented. Management does not believe that any other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying condensed consolidated financial statements.

NOTE 1 - SUMMARY OF SIGNIFICA20

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The Company’s diluted loss per share is the same as the basic loss per share for the years ended December 31, 2017 and 2016, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Twelve Months Ended December 31, 2017 2016 Loss to common shareholders (Numerator) $ (702,163 ) $ (2,124,252 ) Basic and diluted weighted-average number of common shares outstanding (Denominator) 141,305,050 139,186,557
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The Company has excluded the following dilutive securities from the calculation of fully-diluted shares outstanding because the result would have been anti-dilutive: Twelve Months Ended December 31, 2017 2016 Effect of dilutive common stock equivalents: Warrants - - Convertible notes and interest 3,391,300 3,430,547 Total 3,391,300 3,430,547

NOTE 3 INVENTORY (Tables)

NOTE 3 INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	The Company had inventory in the following amounts: December 31, 2017 December 31, 2016 Work in Process $ 24,357 $ 27,986 Finished Goods 34,522 57,224 Total Inventory $ 58,879 $ 85,210

NOTE 4 PROPERTY AND EQUIPMENT (

NOTE 4 PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2017
NOTE 4 PROPERTY AND EQUIPMENT (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	December 31, 2017 December 31, 2016 Manufacturing Equipment- Molds $ 50,963 $ 50,963 Accumulated Depreciation (35,263 ) (35,263 ) $ 15,700 $ 15,700
Estimated Useful Life [Member]
NOTE 4 PROPERTY AND EQUIPMENT (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows: Estimated Useful Life Molds 3 to 7 years

NOTE 5 PATENTS (Tables)

NOTE 5 PATENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	The Company has recorded the following patent costs: December 31, 2017 December 31, 2016 Total Patents $ 77,743 $ 77,743 Accumulated Amortization (61,415 ) (58,605 ) Patent costs, net $ 16,328 $ 19,138
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	The Company recorded amortization expense as follows: Twelve Months Ended December 31, 2017 2016 $ 2,810 $ 1,878
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated amortization expense as of December 31, 2017 is as follows: Years ended December 31, 2018 $ 4,536 2019 4,536 2020 1,809 2021 1,809 2022 and thereafter 3,638 Total $ 16,328

NOTE 7 NOTE PAYABLE AND OTHER24

NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Principal balances of the Related Party loans were as follows: December 31, 2017 December 31, 2016 Claude Ranoux Note $ 21,888 $ 21,888 James Bowdring – Q211 Note 25,000 25,000 James Bowdring- Q411 Note 10,000 10,000 Kathleen Karloff Note 154,000 154,000 Total $ 210,888 $ 210,888
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued liabilities balances include expenses reports for Ms. Karloff, Dr. Ranoux and Mr. Bowdring for expenses they paid for personally related to travel or normal business expenses and are represented in the following table: December 31, 2017 2016 Accounts payable and accrued liabilities $ 38,000 $ 39,000

NOTE 10 INCOME TAXES (Tables)

NOTE 10 INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The Company’s total deferred tax liabilities, deferred tax assets, and deferred tax asset valuation allowances are as of December 31 are as follows: December 31, 2017 December 31, 2016 Total deferred tax assets $ 3,730,000 $ 5,235,000 Less valuation allowance (3,730,000 ) (5,235,000 ) Total deferred tax liabilities - - Net deferred tax asset (liability) $ - $ -
Schedule of Deferred Tax Assets and Liabilities Reported in Financial Statements [Table Text Block]	Those amounts have been presented in the company’s financial statements as of December 31, as follows: December 31, 2017 2016 Deferred tax asset $ - $ - Deferred tax liability - - Net deferred tax asset (liability) $ - $ -

NOTE 1 - SUMMARY OF SIGNIFICA26

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details)	Dec. 22, 2017	Dec. 05, 2008$ / sharesshares	Nov. 30, 2017shares	Sep. 30, 2017shares	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) [Line Items]
Stock Issued During Period, Shares, New Issues			55,556	262,500
Cash and Cash Equivalents, at Carrying Value | $					$ 25,759	$ 152,404	$ 492,004
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Number of Reportable Segments					1
Minimum [Member]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) [Line Items]
Property, Plant and Equipment, Useful Life					3 years
Maximum [Member]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) [Line Items]
Property, Plant and Equipment, Useful Life					7 years
Emy's Salsa Aji Distribution Company, Inc. ("Emy's") [Member]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) [Line Items]
Share Exchange, Number of Shares Retained		14,937,500
Stock Issued During Period, Shares, New Issues		38,307,500
Share Exchange Ratio | $ / shares		$ 357.0197

NOTE 1 - SUMMARY OF SIGNIFICA27

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of Earnings Per Share, Basic and Diluted [Abstract]
Loss to common shareholders (Numerator)	$ (702,163)	$ (2,124,252)
Basic and diluted weighted-average number of common shares outstanding (Denominator)	141,305,050	139,186,557

NOTE 1 - SUMMARY OF SIGNIFICA28

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Effect of dilutive common stock equivalents:
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,391,300	3,430,547
Warrant [Member]
Effect of dilutive common stock equivalents:
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	0
Convertible Debt Securities [Member]
Effect of dilutive common stock equivalents:
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,391,300	3,430,547

NOTE 2 GOING CONCERN (Details)

NOTE 2 GOING CONCERN (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Attributable to Parent	$ (702,163)	$ (2,124,252)
Net Cash Provided by (Used in) Operating Activities	(181,270)	(323,900)
Working Capital (Deficit)	(4,892,418)
Stockholders' Equity Attributable to Parent	$ (4,992,112)	$ (4,617,646)	$ (3,757,002)

NOTE 3 INVENTORY (Details) -

NOTE 3 INVENTORY (Details) - Schedule of Inventory, Current - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Inventory, Current [Abstract]
Work in Process	$ 24,357	$ 27,986
Finished Goods	34,522	57,224
Total Inventory	$ 58,879	$ 85,210

NOTE 4 PROPERTY AND EQUIPMENT31

NOTE 4 PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation	$ 0	$ 0

NOTE 4 PROPERTY AND EQUIPMENT

NOTE 4 PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment - Minimum [Member]	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years

NOTE 4 PROPERTY AND EQUIPME33

NOTE 4 PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
	$ 15,700	$ 15,700
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Manufacturing Equipment- Molds	50,963	50,963
Accumulated Depreciation	$ (35,263)	$ (35,263)

NOTE 5 PATENTS (Details)

NOTE 5 PATENTS (Details)	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Finite-Lived Intangible Asset, Useful Life	20 years

NOTE 5 PATENTS (Details) - Sc

NOTE 5 PATENTS (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Finite-Lived Intangible Assets [Abstract]
Total Patents	$ 77,743	$ 77,743
Accumulated Amortization	(61,415)	(58,605)
Patent costs, net	$ 16,328	$ 19,138

NOTE 5 PATENTS (Details) - Fi

NOTE 5 PATENTS (Details) - Finite-lived Intangible Assets Amortization Expense - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-lived Intangible Assets Amortization Expense [Abstract]
	$ 2,810	$ 1,878

NOTE 5 PATENTS (Details) - 37

NOTE 5 PATENTS (Details) - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Abstract]
2,018	$ 4,536
2,019	4,536
2,020	1,809
2,021	1,809
2022 and thereafter	3,638
Total	$ 16,328	$ 19,138

NOTE 6 CONVERTIBLE NOTES AND 38

NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) - USD ($)	1 Months Ended		12 Months Ended			66 Months Ended
	Mar. 31, 2017	Aug. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2009	May 31, 2015	May 31, 2010
NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount		$ 131,722
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Debt Instrument, Term		3 years
Excess Value of Warrant Liability			$ 40,869	$ 0
Debt Conversion, Original Debt, Amount			57,940	0
Bridge Note [Member]
NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount	$ 10,000					$ 535,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	341,000
Gains (Losses) on Restructuring of Debt	$ (40,869)
Note Payable - Long Time Vendor [Member]
NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Interest Expense, Debt			9,330	2,760
Convertible Debt [Member]
NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Convertible Debt, Current			0	10,000
Convertible Debt [Member] | Bridge Note [Member]
NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount					$ 545,000
Debt Instrument, Term					1 year
Debt Instrument, Convertible, Conversion Price (in Dollars per share)					$ 0.10
Debt Instrument, Convertible, Terms of Conversion Feature					If the Company were to issue any new shares of common stock within 24 months of the date of the Bridge Notes at a price below the Original Conversion Price, then the conversion price of the Bridge Notes would be adjusted to reflect the new lower price.
Class of Warrant or Rights, Granted (in Shares)					5,750,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					$ 0.20
Debt Instrument, Convertible, Beneficial Conversion Feature					$ 1,473,710
Debt Instrument, Unamortized Discount					545,000
Other Noncash Expense					1,341,884
Debt Instrument, Convertible, Carrying Amount of Equity Component					1,719,666
Excess Value of Warrant Liability					1,326,492
Derivative Liability, Current					2,668,371
Interest Expense, Debt			$ 0	$ 750
Convertible Debt [Member] | Bridge Note [Member] | Discount Related to Beneficial Conversion Feature [Member]
NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Unamortized Discount					151,826
Convertible Debt [Member] | Bridge Note [Member] | Debt Discount Related to Warrants [Member]
NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Unamortized Discount					$ 393,174
Convertible Debt [Member] | Q2 Note [Member]
NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Derivative Liability, Current							$ 545,000
Convertible Debt [Member] | Minimum [Member] | Bridge Note [Member]
NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					10.00%
Convertible Debt [Member] | Maximum [Member] | Bridge Note [Member]
NOTE 6 CONVERTIBLE NOTES AND NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					12.00%

NOTE 7 NOTE PAYABLE AND OTHER39

NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Details) - USD ($)	Dec. 28, 2009	May 01, 2009	Mar. 26, 2009	Aug. 31, 2016	Nov. 30, 2012	Nov. 30, 2011	Sep. 30, 2011	Apr. 30, 2011	May 31, 2009	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2011	Mar. 05, 2009	Dec. 31, 2008
NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Debt Instrument, Face Amount				$ 131,722
Debt Instrument, Term				3 years
Notes Payable, Related Parties										$ 210,888	$ 210,888
Interest Expense, Related Party										11,543	13,088
President, Director, and Chief Scientific Officer [Member]
NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current													$ 21,888			$ 96,462
Debt Instrument, Interest Rate, Stated Percentage			5.00%
Debt Instrument, Maturity Date			Oct. 31, 2018
Repayments of Related Party Debt										0	0
Chief Executive Officer [Member]
NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current														$ 88,000
Debt Instrument, Interest Rate, Stated Percentage												0.00%			5.00%
Debt Instrument, Maturity Date		Oct. 31, 2018
Debt Instrument, Face Amount															$ 75,000
Proceeds from Related Party Debt									$ 13,000			$ 66,000
Notes Payable, Related Parties										154,000	154,000
Immediate Family Member of Management or Principal Owner [Member]
NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage						10.00%		10.00%
Repayments of Related Party Debt							$ 25,000
Debt Instrument, Face Amount	$ 100,000					$ 10,000		$ 50,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)	666,667
Debt Instrument, Term						2 months		2 months
Notes Payable, Related Parties													$ 25,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)						$ 0.01							$ 0.03
Class of Warrant or Rights, Granted (in Shares)						500,000		1,666,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$ 0.02		$ 0.03
Debt Instrument, Convertible, Beneficial Conversion Feature						$ 2,345		$ 39,500
Debt Instrument, Convertible, Carrying Amount of Equity Component						$ 4,076		$ 45,500
Immediate Family Member of Management or Principal Owner [Member] | Building [Member]
NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals					$ 4,800
Operating Leases, Rent Expense										$ 1,700	$ 4,100

NOTE 7 NOTE PAYABLE AND OTHER

NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Details) - Schedule of Related Party Transactions - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Related Party Loans	$ 210,888	$ 210,888
Director [Member]
Related Party Transaction [Line Items]
Related Party Loans	21,888	21,888
Immediate Family Member of Management or Principal Owner [Member]
Related Party Transaction [Line Items]
Related Party Loans			$ 25,000
Immediate Family Member of Management or Principal Owner [Member] | Q2 2011 Note [Member]
Related Party Transaction [Line Items]
Related Party Loans	25,000	25,000
Immediate Family Member of Management or Principal Owner [Member] | Q4 2011 Note [Member]
Related Party Transaction [Line Items]
Related Party Loans	10,000	10,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Related Party Loans	$ 154,000	$ 154,000

NOTE 7 NOTE PAYABLE AND OTH41

NOTE 7 NOTE PAYABLE AND OTHER RELATED PARTY TRANSACTIONS (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable and accrued liabilities	$ 38,000	$ 39,000

NOTE 8 STOCKHOLDERS' EQUITY (De

NOTE 8 STOCKHOLDERS' EQUITY (Details) - USD ($)	1 Months Ended						12 Months Ended		66 Months Ended
	Nov. 30, 2017	Sep. 30, 2017	Jun. 30, 2017	Apr. 30, 2017	Mar. 31, 2017	May 31, 2016	Dec. 31, 2017	Dec. 31, 2016	May 31, 2015
NOTE 8 STOCKHOLDERS' EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)	395,550	133,960	99,412	51,750	196,000	511,000
Stock Issued During Period, Value, Issued for Services	$ 79,215	$ 28,576	$ 30,898	$ 17,201	$ 59,242	$ 183,608	$ 215,132	$ 1,263,608
Debt Conversion, Original Debt, Amount							57,940	$ 0
Stock Issued During Period, Shares, New Issues (in Shares)	55,556	262,500
Stock Issued During Period, Value, New Issues	$ 10,000	$ 44,625					$ 54,625
Stock Issued During Period, Shares, Share-based Compensation, Gross (in Shares)						3,000,000
Stock Issued During Period, Value, Share-based Compensation, Gross						$ 1,080,000
Bridge Note [Member]
NOTE 8 STOCKHOLDERS' EQUITY (Details) [Line Items]
Debt Conversion, Original Debt, Amount					$ 10,000				$ 535,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)					341,000
Gains (Losses) on Restructuring of Debt					$ (40,869)

NOTE 10 INCOME TAXES (Details)

NOTE 10 INCOME TAXES (Details) - USD ($)	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards		$ 9,100,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Income Tax Expense (Benefit)	$ 1,680,000	0	$ 0
Deferred Tax Assets, Valuation Allowance	$ 1,680,000	$ 3,730,000	$ 5,235,000

NOTE 10 INCOME TAXES (Detail

NOTE 10 INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2017	Dec. 22, 2017	Dec. 31, 2016
Schedule of Deferred Tax Assets and Liabilities [Abstract]
Total deferred tax assets	$ 3,730,000		$ 5,235,000
Less valuation allowance	(3,730,000)	$ (1,680,000)	(5,235,000)
Total deferred tax liabilities	0		0
Net deferred tax asset (liability)	$ 0		$ 0

NOTE 10 INCOME TAXES (Deta45

NOTE 10 INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities Reported in Financial Statements - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Deferred Tax Assets and Liabilities Reported in Financial Statements [Abstract]
Deferred tax asset	$ 0	$ 0
Deferred tax liability	0	0
Net deferred tax asset (liability)	$ 0	$ 0

NOTE 12 SUBSEQUENT EVENTS (Deta

NOTE 12 SUBSEQUENT EVENTS (Details) - USD ($)	1 Months Ended									12 Months Ended
	Mar. 31, 2018	Feb. 28, 2018	Jan. 31, 2018	Nov. 30, 2017	Sep. 30, 2017	Jun. 30, 2017	Apr. 30, 2017	Mar. 31, 2017	May 31, 2016	Dec. 31, 2017	Dec. 31, 2016
NOTE 12 SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross									3,000,000
Stock Issued During Period, Value, Share-based Compensation, Gross									$ 1,080,000
Stock Issued During Period, Shares, New Issues				55,556	262,500
Stock Issued During Period, Value, New Issues				$ 10,000	$ 44,625					$ 54,625
Stock Issued During Period, Shares, Issued for Services				395,550	133,960	99,412	51,750	196,000	511,000
Stock Issued During Period, Value, Issued for Services				$ 79,215	$ 28,576	$ 30,898	$ 17,201	$ 59,242	$ 183,608	$ 215,132	$ 1,263,608
Subsequent Event [Member]
NOTE 12 SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross			1,000,000
Stock Issued During Period, Value, Share-based Compensation, Gross			$ 115,000
Stock Issued During Period, Shares, New Issues			100,000
Stock Issued During Period, Value, New Issues			$ 15,000
Stock Issued During Period, Shares, Issued for Services	20,000	90,900	441,426
Stock Issued During Period, Value, Issued for Services	$ 3,800	$ 10,000	$ 52,864